{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:38:05Z","timestamp":1786995485124,"version":"build-2736575974"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.pcad.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T03:09:28Z","timestamp":1470452968000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?"],"prefix":"10.1016","volume":"59","author":[{"given":"Lane B.","family":"Benes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil S.","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25 Pt B","key":"10.1016\/j.pcad.2016.08.001_bb0005","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.pcad.2016.08.001_bb0010","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.pcad.2016.08.001_bb0015","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.pcad.2016.08.001_bb0020","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.pcad.2016.08.001_bb0025","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.08.001_bb0030","first-page":"1","article-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012","volume":"177","author":"Gu","year":"2014","journal-title":"NCHS Data Brief"},{"issue":"21","key":"10.1016\/j.pcad.2016.08.001_bb0035","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.pcad.2016.08.001_bb0040","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"European Association for Cardiovascular Prevention & Rehabilitation","year":"2011","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.pcad.2016.08.001_bb0045","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bj\u00f6rnsson","year":"2012","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.pcad.2016.08.001_bb0050","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.27157","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","author":"Russo","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pcad.2016.08.001_bb0055","first-page":"246","article-title":"Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry","volume":"106","author":"Perdices","year":"2014","journal-title":"Rev Esp Enferm Dig"},{"issue":"3","key":"10.1016\/j.pcad.2016.08.001_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151587","article-title":"High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort","volume":"11","author":"Clarke","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pcad.2016.08.001_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"issue":"1","key":"10.1016\/j.pcad.2016.08.001_bb0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jgh.12657","article-title":"Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study","volume":"30","author":"Chang","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.pcad.2016.08.001_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/jcpt.12377","article-title":"Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea","author":"Kim","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1016\/j.pcad.2016.08.001_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2010.10.036","article-title":"Differential metabolic effects of distinct statins","volume":"215","author":"Koh","year":"2011","journal-title":"Atherosclerosis"},{"issue":"9716","key":"10.1016\/j.pcad.2016.08.001_bb0085","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pcad.2016.08.001_bb0090","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.amjcard.2012.12.037","article-title":"Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus","volume":"111","author":"Navarese","year":"2013","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.pcad.2016.08.001_bb0095","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"9841","key":"10.1016\/j.pcad.2016.08.001_bb0100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pcad.2016.08.001_bb0105","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2125.2012.04403.x","article-title":"Statins and risk of treated incident diabetes in a primary care population","volume":"75","author":"Zaharan","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pcad.2016.08.001_bb0110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.amjcard.2015.11.009","article-title":"Impact of Statin Use on Development of New-Onset Diabetes Mellitus in Asian Population","volume":"117","author":"Rha","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2016.08.001_bb0115","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.pcad.2016.08.001_bb0120","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","article-title":"Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative","volume":"172","author":"Culver","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pcad.2016.08.001_bb0125","doi-asserted-by":"crossref","DOI":"10.1111\/jdi.12483","article-title":"Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes","author":"Huang","year":"2016","journal-title":"J Diabetes Investig"},{"issue":"2","key":"10.1016\/j.pcad.2016.08.001_bb0130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jacl.2012.06.006","article-title":"Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting","volume":"7","author":"Cziraky","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.pcad.2016.08.001_bb0135","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"10.1016\/j.pcad.2016.08.001_bb0140","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2169\/internalmedicine.50.4484","article-title":"Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration","volume":"50","author":"Oshima","year":"2011","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.pcad.2016.08.001_bb0145","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.pcad.2016.08.001_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002040","article-title":"Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information","volume":"3","author":"Chang","year":"2013","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.pcad.2016.08.001_bb0155","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bcp.12367","article-title":"Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment","volume":"78","author":"van Staa","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"15","key":"10.1016\/j.pcad.2016.08.001_bb0160","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2012.489","article-title":"Use of administrative data to estimate the incidence of statin-related rhabdomyolysis","volume":"307","author":"Floyd","year":"2012","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.pcad.2016.08.001_bb0165","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.pcad.2016.08.001_bb0170","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3138\/ptc.2012-65","article-title":"Statin-induced rhabdomyolysis: a comprehensive review of case reports","volume":"66","author":"Mendes","year":"2014","journal-title":"Physiother Can"},{"issue":"5","key":"10.1016\/j.pcad.2016.08.001_bb0175","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.amjmed.2006.02.007","article-title":"Clinical perspectives of statin-induced rhabdomyolysis","volume":"119","author":"Antons","year":"2006","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.pcad.2016.08.001_bb0180","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00002512-200724050-00006","article-title":"Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins","volume":"24","author":"Egger","year":"2007","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.pcad.2016.08.001_bb0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/14740338.5.1.145","article-title":"Statin\/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions","volume":"5","author":"Davidson","year":"2006","journal-title":"Expert Opin Drug Saf"},{"issue":"8A","key":"10.1016\/j.pcad.2016.08.001_bb0190","doi-asserted-by":"crossref","first-page":"27C","DOI":"10.1016\/j.amjcard.2005.12.007","article-title":"Statin safety and drug interactions: clinical implications","volume":"97","author":"Bottorff","year":"2006","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2016.08.001_bb0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.1995.03530010049034","article-title":"Systems analysis of adverse drug events. ADE Prevention Study Group","volume":"274","author":"Leape","year":"1995","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pcad.2016.08.001_bb0200","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF03167690","article-title":"The potential for drug interactions with statin therapy in Ireland","volume":"169","author":"Heerey","year":"2000","journal-title":"Ir J Med Sci"},{"issue":"9","key":"10.1016\/j.pcad.2016.08.001_bb0205","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1345\/aph.1A333","article-title":"Hospital admissions resulting from preventable adverse drug reactions","volume":"36","author":"McDonnell","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.pcad.2016.08.001_bb0210","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","article-title":"Update: clinically significant cytochrome P-450 drug interactions","volume":"18","author":"Michalets","year":"1998","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.pcad.2016.08.001_bb0215","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/14779072.1.4.495","article-title":"Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia","volume":"1","author":"Rosenson","year":"2003","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"10.1016\/j.pcad.2016.08.001_bb0220","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pcad.2016.08.001_bb0225","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2125.2003.01720.x","article-title":"Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects","volume":"55","author":"Cooper","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.pcad.2016.08.001_bb0230","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.pcad.2016.08.001_bb0235","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1345\/aph.10228","article-title":"Rhabdomyolysis and HMG-CoA reductase inhibitors","volume":"35","author":"Omar","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"8A","key":"10.1016\/j.pcad.2016.08.001_bb0240","doi-asserted-by":"crossref","first-page":"61C","DOI":"10.1016\/j.amjcard.2005.12.011","article-title":"Statin safety: an assessment using an administrative claims database","volume":"97","author":"Cziraky","year":"2006","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2016.08.001_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157531","article-title":"Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir\/Ritonavir: A Randomized, Double-Blind, Crossover Study","volume":"11","author":"Wongprikorn","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pcad.2016.08.001_bb0250","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","article-title":"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells","volume":"15","author":"Kameyama","year":"2005","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"10.1016\/j.pcad.2016.08.001_bb0255","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.pcad.2016.08.001_bb0260","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.pcad.2016.08.001_bb0265","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/FJC.0000000000000246","article-title":"Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations","volume":"66","author":"Luzum","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"issue":"37","key":"10.1016\/j.pcad.2016.08.001_bb0270","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001268","article-title":"Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies","volume":"94","author":"Hou","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.pcad.2016.08.001_bb0275","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.pcad.2016.08.001_bb0280","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2016.08.001_bb0285","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ahj.2013.01.025","article-title":"Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy","volume":"165","author":"Danik","year":"2013","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.pcad.2016.08.001_bb0290","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"DeGorter","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"issue":"5","key":"10.1016\/j.pcad.2016.08.001_bb0295","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00228-014-1661-6","article-title":"Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2","volume":"70","author":"Ferrari","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.pcad.2016.08.001_bb0300","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01213011-200506000-00007","article-title":"Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage","volume":"15","author":"Wilke","year":"2005","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"10.1016\/j.pcad.2016.08.001_bb0305","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy","volume":"79","author":"Hermann","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.pcad.2016.08.001_bb0310","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2217\/pgs.13.115","article-title":"Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9\/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients","volume":"14","author":"Lee","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.pcad.2016.08.001_bb0315","article-title":"Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants","volume":"5","author":"Talameh","year":"2014","journal-title":"J Pharmacogenomics Pharmacoproteomics"},{"issue":"23 Suppl. 1","key":"10.1016\/j.pcad.2016.08.001_bb0320","first-page":"III50","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pcad.2016.08.001_bb0325","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","article-title":"The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment","volume":"78","author":"Fiegenbaum","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pcad.2016.08.001_bb0330","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/tpj.2011.59","article-title":"Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy","volume":"13","author":"Becker","year":"2013","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"10.1016\/j.pcad.2016.08.001_bb0335","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00280-004-0931-x","article-title":"Single nucleotide polymorphisms modify the transporter activity of ABCG2","volume":"56","author":"Morisaki","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.pcad.2016.08.001_bb0340","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40273-013-0045-6","article-title":"Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia","volume":"31","author":"Sorich","year":"2013","journal-title":"PharmacoEconomics"},{"issue":"8","key":"10.1016\/j.pcad.2016.08.001_bb0345","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/0091270009355161","article-title":"Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans","volume":"50","author":"Man","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.pcad.2016.08.001_bb0350","first-page":"27","article-title":"Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective","volume":"139","author":"Umamaheswaran","year":"2014","journal-title":"Indian J Med Res"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016300779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016300779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:41:40Z","timestamp":1749037300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062016300779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0033062016300779"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2016.08.001","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}